# A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct07489716/  
OnCo record `nct07489716` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of SHR-1826 in non-small-cell lung cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.

## Summary

A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT07489716 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 90 participants planned, started 2026-04-29 and due to reach its primary completion in 2028-08. Interventions recorded: SHR-1826.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07489716
- Phase: 2
- Setting: A Phase II Clinical Study on the Efficacy, Safety, and Pharmacokinetics of SHR-1826 for Injection in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Enrolled: 90

## Sources

- ClinicalTrials.gov NCT07489716: https://clinicaltrials.gov/study/NCT07489716

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct07489716.json